Stock Research for MYL

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

MYL Stock Chart & Research Data

The MYL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MYL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


MYL Due diligence Resources & Stock Charts

The MYL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MYL Detailed Price Forecast - CNN Money CNN View MYL Detailed Summary - Google Finance
Yahoo View MYL Detailed Summary - Yahoo! Finance Zacks View MYL Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View MYL Trends & Analysis - Trade-Ideas Barrons View MYL Major Holders - Barrons
NASDAQ View MYL Call Transcripts - NASDAQ Seeking View MYL Breaking News & Analysis - Seeking Alpha
Spotlight View MYL Annual Report - CompanySpotlight.com OTC Report View MYL OTC Short Report - OTCShortReport.com
TradeKing View MYL Fundamentals - TradeKing Charts View MYL SEC Filings - Bar Chart
WSJ View Historical Prices for MYL - The WSJ Morningstar View Performance/Total Return for MYL - Morningstar
MarketWatch View the Analyst Estimates for MYL - MarketWatch CNBC View the Earnings History for MYL - CNBC
StockMarketWatch View the MYL Earnings - StockMarketWatch MacroAxis View MYL Buy or Sell Recommendations - MacroAxis
Bullish View the MYL Bullish Patterns - American Bulls Short Pains View MYL Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View MYL Stock Mentions - StockTwits PennyStocks View MYL Stock Mentions - PennyStockTweets
Twitter View MYL Stock Mentions - Twitter Invest Hub View MYL Investment Forum News - Investor Hub
Yahoo View MYL Stock Mentions - Yahoo! Message Board Seeking Alpha View MYL Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for MYL - SECform4.com Insider Cow View Insider Transactions for MYL - Insider Cow
CNBC View MYL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MYL - OTC Markets
Yahoo View Insider Transactions for MYL - Yahoo! Finance NASDAQ View Institutional Holdings for MYL - NASDAQ


Stock Charts

FinViz View MYL Stock Insight & Charts - FinViz.com StockCharts View MYL Investment Charts - StockCharts.com
BarChart View MYL Stock Overview & Charts - BarChart Trading View View MYL User Generated Charts - Trading View




Latest Financial News for MYL


Theravance, Mylan Report Positive Data on COPD Drug Yupelri
Posted on Tuesday September 18, 2018

Theravance (TBPH) and partner Mylan post positive data from a late-stage program on COPD Drug, Yupelri.


Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at the European Respiratory Society International Congress
Posted on Monday September 17, 2018

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that positive new data from the companies' Phase 3 clinical program for YUPELRI™ (revefenacin) inhalation solution were featured in an oral presentation at the European Respiratory Society (ERS) International Congress 2018, which is being held in Paris, France on September 15-19, 2018. Presented data showed reductions in the rates of chronic obstructive pulmonary disease (COPD) exacerbations ranging from 15% to 18% in moderate to very severe COPD patients administered once-daily YUPELRI for up to 52 weeks as compared to placebo and tiotropium (Spiriva® HandiHaler®). While the YUPELRI Phase 3 program was not designed or powered to achieve statistical significance on differences in COPD exacerbation rates, researchers were interested in a post-hoc analysis of data from the studies to identify trends in this area.


The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Posted on Sunday September 16, 2018

Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...


See what the IHS Markit Score report has to say about Mylan NV.
Posted on Saturday September 15, 2018

Mylan NV NASDAQ/NGS:MYL


Stock Market & Investing Books

Enter a stock symbol to view the stock details.